These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2471008)

  • 21. Hepatic lipase mediates an increase in selective uptake of high-density lipoprotein-associated cholesteryl esters by human Hep 3B hepatoma cells in culture.
    Rinninger F; Mann WA; Kaiser T; Ahle S; Meyer N; Greten H
    Atherosclerosis; 1998 Dec; 141(2):273-85. PubMed ID: 9862176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doxazosin: a new alpha 1-adrenergic antagonist.
    Babamoto KS; Hirokawa WT
    Clin Pharm; 1992 May; 11(5):415-27. PubMed ID: 1349855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic and pharmacodynamic studies with two alpha-adrenoceptor antagonists, doxazosin and prazosin in the rabbit.
    Hamilton CA; Reid JL; Vincent J
    Br J Pharmacol; 1985 Sep; 86(1):79-87. PubMed ID: 2864970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upregulation of low density lipoprotein receptor activity by tumor necrosis factor, a process independent of tumor necrosis factor-induced lipid synthesis and secretion.
    Liao W; Florén CH
    Lipids; 1994 Oct; 29(10):679-84. PubMed ID: 7861934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Studies of serum lipids in hypercholesterolaemic rabbits treated with doxazosin.
    Leren TP; Berg K
    Scand J Clin Lab Invest; 1988 Jun; 48(4):313-7. PubMed ID: 2907180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension.
    Young RA; Brogden RN
    Drugs; 1988 May; 35(5):525-41. PubMed ID: 2899495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Doxazosin, an alpha1-adrenergic antihypertensive agent, decreases serum oxidized LDL.
    Kinoshita M; Shimazu N; Fujita M; Fujimaki Y; Kojima K; Mikuni Y; Horie E; Teramoto T
    Am J Hypertens; 2001 Mar; 14(3):267-70. PubMed ID: 11281239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of doxazosin, an alpha 1-adrenergic inhibitor, on plasma lipid and lipoprotein levels, low density lipoprotein metabolism and cholesterol absorption in cynomolgus monkeys.
    Stucchi AF; Vespa DB; Terpstra AH; Nicolosi RJ
    Atherosclerosis; 1993 Nov; 103(2):255-66. PubMed ID: 8292100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism.
    Pool JL
    Am Heart J; 1991 Jan; 121(1 Pt 2):251-9; discussion 259-60. PubMed ID: 1824647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholesterol metabolism. Effect of 26-thiacholesterol and 26-aminocholesterol, analogues of 26-hydroxycholesterol, on cholesterol synthesis and low-density-lipoprotein-receptor binding.
    Miao E; Wilson SR; Javitt NB
    Biochem J; 1988 Nov; 255(3):1049-52. PubMed ID: 2850793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.
    Torvik D; Madsbu HP
    Am J Cardiol; 1987 May; 59(14):68G-72G. PubMed ID: 2884855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
    Kyprianou N; Benning CM
    Cancer Res; 2000 Aug; 60(16):4550-5. PubMed ID: 10969806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin.
    Thomas D; Wimmer AB; Wu K; Hammerling BC; Ficker EK; Kuryshev YA; Kiehn J; Katus HA; Schoels W; Karle CA
    Naunyn Schmiedebergs Arch Pharmacol; 2004 May; 369(5):462-72. PubMed ID: 15098086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological evaluation of prazosin- and doxazosin-related compounds with modified piperazine ring.
    Giardinà D; Crucianelli M; Marucci G; Melchiorre C; Polidori C; Pompei P; Massi M
    Arzneimittelforschung; 1996 Nov; 46(11):1054-9. PubMed ID: 8955864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.
    Pool JL; Lenz ML; Taylor AA
    J Hum Hypertens; 1990 Oct; 4 Suppl 3():23-33. PubMed ID: 1979819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
    Keledjian K; Kyprianou N
    J Urol; 2003 Mar; 169(3):1150-6. PubMed ID: 12576871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of doxazosin on vascular collagen synthesis, arterial pressure and serum lipids in the spontaneously hypertensive rat.
    Chichester CO; Rodgers RL
    J Cardiovasc Pharmacol; 1987; 10 Suppl 9():S21-6. PubMed ID: 2447437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipoprotein metabolism by rat hepatomas. Studies on the etiology of defective dietary feedback inhibition of cholesterol synthesis.
    Barnard GF; Erickson SK; Cooper AD
    J Clin Invest; 1984 Jul; 74(1):173-84. PubMed ID: 6330173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of alpha 1-inhibition on lipid metabolism in the rat.
    Woodside WF; Swindell AC
    J Cardiovasc Pharmacol; 1987; 10 Suppl 9():S27-34. PubMed ID: 2447438
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interactions of doxazosin with insulin or glucagon in the ob/ob mouse.
    Swindell AC; Valentine JJ
    J Cardiovasc Pharmacol; 1989; 13 Suppl 2():S20-4; discussion S24. PubMed ID: 2471011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.